U.S. markets close in 4 hours 52 minutes

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
43.87-1.88 (-4.10%)
As of 3:52PM BST. Market open.

Shield Therapeutics plc

Northern Design Centre
Baltic Business Quarter
Gateshead NE8 3DF
United Kingdom
44 1915 118 500

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Mr. Timothy William WattsCEO & DirectorN/AN/A1958
Mr. Hans-Peter RudolfChief Financial OfficerN/AN/AN/A
Fleur WoodDirector of Investor RelationsN/AN/AN/A
Ms. Lucy Huntington-BaileyGen. Counsel & Company Sec.N/AN/AN/A
Ms. Suzanne WoodGroup HR DirectorN/AN/AN/A
Mr. Paul StecklerChief Commercial OfficerN/AN/AN/A
Ms. Carol AkinolaHead of Pharmacovigilance & Medical InformationN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Corporate Governance

Shield Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.